-
Article
Open AccessTen years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies
In 2007, Omnitrope® was the first biosimilar recombinant human growth hormone (rhGH) to be approved in Sweden for treatment in adults and children. Over 10 years’ safety and effectiveness data for biosimilar r...
-
Article
Open AccessCorrection to: Severity of depression, anxious distress and the risk of type 2 diabetes – a population-based cohort study in Sweden
It was highlighted that the original article [1] contained an error in the flow chart in Fig. 1.
-
Article
Open AccessSeverity of depression, anxious distress and the risk of type 2 diabetes – a population-based cohort study in Sweden
Previous studies assessing the relationship between depression and diabetes mellitus did not consider the severity of depression. In the present study we assessed the risk of develo** type 2 diabetes mellitu...
-
Article
A serum 25-hydroxyvitamin D concentration-associated genetic variant in DHCR7 interacts with type 2 diabetes status to influence subclinical atherosclerosis (measured by carotid intima–media thickness)
The findings of studies investigating whether or not low serum 25-hydroxyvitamin D [25(OH)D] concentration promotes development of atherosclerosis have been contradictory. The present study employed a Mendelia...
